首页 › 基金 › Context Capital Management, LLC › BBIO
Context Capital Management, LLC 对 BBIO 的持仓历史
BRIDGEBIO PHARMA INC · 医疗保健
Context Capital Management, LLC 在 Q2 2026 的 13F 申报中披露持有 BBIO(BRIDGEBIO PHARMA INC)56,666,000 股,市值约 US$62.9M,约占其申报组合的 1.83%,在其申报持仓中市值排名第 18 位。 Context Capital Management, LLC 最近 12 个申报季度中有 12 个季度披露了 BBIO 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Context Capital Management, LLC 对 BBIO 的持仓演变
Context Capital Management, LLC 于 Q3 2023 首次披露 BBIO 持仓:6,110 股(约 US$5.9M)。 该持仓在 Q1 2025 达到峰值 70,404 股,市值约 US$63.47B。 在 12 次申报中,Context Capital Management, LLC 8 次增持、3 次减持、0 次保持不变。 最近一期申报(Q2 2026)显示持股 56,666,000 股、市值约 US$62.9M,环比减持 -14,588,000 股。。 持仓曾出现大幅变动:Q4 2023 增持约 1700% (随后一个季度股价下跌 23%)、Q2 2024 增持约 43845% (随后一个季度股价基本持平)、Q4 2025 增持约 81403% (随后一个季度股价下跌 3%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 6.11K | $5.86M | 新进 |
| Q4 2023 | 110.00K | $133.16M | 增持 |
| Q1 2024 | 110 | $118.22M | 减持 |
| Q2 2024 | 48.34K | $38.52B | 增持 |
| Q3 2024 | 61.34K | $51.52B | 增持 |
| Q4 2024 | 68.90K | $59.12B | 增持 |
| Q1 2025 | 70.40K | $63.47B | 增持 |
| Q2 2025 | 72.70K | $68.05M | 增持 |
| Q3 2025 | 97.85K | $96.70M | 增持 |
| Q4 2025 | 79.75M | $89.82M | 增持 |
| Q1 2026 | 71.25M | $79.94M | 减持 |
| Q2 2026 | 56.67M | $62.92M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 BBIO 与 13F 数据
BBIO(BRIDGEBIO PHARMA INC)属于医疗保健行业。我们追踪的基金中还有 47 只申报持有 BBIO,申报仓位最大的包括:Jupiter Topco LLC (US$1.05B), 骏利亨德森集团 (US$978.6M), 法拉龙资本管理 (US$800.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 BBIO 的基金
- Jupiter Topco LLC 14.11M 股 · $1.05B · Q2 2026
- 骏利亨德森集团 13.18M 股 · $978.61M · Q1 2026
- 法拉龙资本管理 10.74M 股 · $800.14M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 10.74M 股 · $800.14M · Q2 2026
- 维京环球投资 9.95M 股 · $741.02M · Q2 2026
- VIKING GLOBAL INVESTORS LP 9.95M 股 · $741.02M · Q2 2026
- Aisling Capital Management LP 4.59M 股 · $341.83M · Q2 2026
- SC US (TTGP), LTD. 1.86M 股 · $138.56M · Q2 2026
- STEELHEAD PARTNERS LLC 70.00M 股 · $124.78M · Q2 2026
- CAPSTONE INVESTMENT ADVISORS, LLC 69.87M 股 · $124.49M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.55M 股 · $115.31M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 1.37M 股 · $102.27M · Q2 2026
更多关于 Context Capital Management, LLC
常见问题
How long has Context Capital Management, LLC held BBIO?
Context Capital Management, LLC has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Context Capital Management, LLC's current position in BBIO?
As of Q2 2026, Context Capital Management, LLC holds 56.67M shares of BBIO (BRIDGEBIO PHARMA INC), valued at $62.92M, representing 1.83% of its reported portfolio and ranking #18.
Has Context Capital Management, LLC been buying or selling BBIO?
In the latest 13F filing (Q2 2026), Context Capital Management, LLC reduced its position in BBIO. The position peaked in Q1 2025 at 70.40K shares.
Which other funds hold BBIO?
Other major institutional holders of BBIO include Jupiter Topco LLC, 骏利亨德森集团, 法拉龙资本管理, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.